NASDAQ:OPNT - Opiant Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$13.15 -0.87 (-6.21 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$13.15
Today's Range$13.00 - $13.74
52-Week Range$12.02 - $29.55
Volume33,462 shs
Average Volume28,767 shs
Market Capitalization$50.36 million
P/E Ratio-1.85
Dividend YieldN/A
Beta0.57

Headlines

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:
DateHeadline
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call TranscriptOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 22 at 8:43 AM
Opiant Pharmaceuticals (OPNT) Issues Quarterly  Earnings ResultsOpiant Pharmaceuticals (OPNT) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 22 at 7:38 AM
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - March 21 at 7:38 PM
EXXARO RESOURCE/S (EXXAY) & Opiant Pharmaceuticals (OPNT) Head to Head ReviewEXXARO RESOURCE/S (EXXAY) & Opiant Pharmaceuticals (OPNT) Head to Head Review
www.americanbankingnews.com - March 21 at 4:16 AM
Opiant Pharmaceuticals (OPNT) to Release Quarterly Earnings on ThursdayOpiant Pharmaceuticals (OPNT) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - March 19 at 9:47 AM
Opiant Pharmaceuticals, Inc. Estimate MomentumOpiant Pharmaceuticals, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 7:49 PM
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
finance.yahoo.com - March 18 at 7:49 PM
Adamis Pharma stock jumps after FDA agrees to review injectable opioid-overdose treatmentAdamis Pharma stock jumps after FDA agrees to review injectable opioid-overdose treatment
www.marketwatch.com - March 15 at 8:38 AM
 Opiant Pharmaceuticals Inc (OPNT) Given Consensus Recommendation of "Strong Buy" by Brokerages Opiant Pharmaceuticals Inc (OPNT) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 14 at 11:13 AM
Opiant Pharmaceuticals Inc (OPNT) Insider Sells $149,500.00 in StockOpiant Pharmaceuticals Inc (OPNT) Insider Sells $149,500.00 in Stock
www.americanbankingnews.com - March 4 at 7:20 PM
BRIEF-Opiant Pharmaceuticals - Discontinuing Development Of OPNT001 For Treatment Of Bulimia NervosaBRIEF-Opiant Pharmaceuticals - Discontinuing Development Of OPNT001 For Treatment Of Bulimia Nervosa
www.msn.com - February 21 at 6:52 PM
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia NervosaOpiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
finance.yahoo.com - February 21 at 6:52 PM
Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?
finance.yahoo.com - February 6 at 6:26 PM
OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…
finance.yahoo.com - January 9 at 6:54 PM
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi - NasdaqOpiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi - Nasdaq
www.nasdaq.com - December 26 at 8:32 AM
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent - GlobeNewswireOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent - GlobeNewswire
globenewswire.com - December 26 at 8:32 AM
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from SanofiOpiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
finance.yahoo.com - December 26 at 8:32 AM
Opiant Pharmaceuticals announces FDA Orange Book listing for new NARCAN nasal spray patentOpiant Pharmaceuticals announces FDA Orange Book listing for new NARCAN nasal spray patent
seekingalpha.com - December 24 at 5:12 PM
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray PatentOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
finance.yahoo.com - December 24 at 8:23 AM
Adamis: An Exciting Pipeline Candidate Moves ForwardAdamis: An Exciting Pipeline Candidate Moves Forward
seekingalpha.com - December 20 at 8:29 AM
This Killer Opioid Could Become a Weapon of Mass Destruction - BloombergThis Killer Opioid Could Become a Weapon of Mass Destruction - Bloomberg
www.bloomberg.com - December 14 at 8:28 AM
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
finance.yahoo.com - November 20 at 5:14 PM
New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 19 at 8:24 AM
OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…
finance.yahoo.com - November 8 at 5:31 PM
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 5:39 PM
Opnet Technologies, Inc. (OPNT) Reports Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia NervosaOpnet Technologies, Inc. (OPNT) Reports Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
www.streetinsider.com - November 6 at 8:26 AM
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia NervosaOpiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
finance.yahoo.com - November 5 at 9:01 AM
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on ...Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on ...
globenewswire.com - November 2 at 5:15 PM
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7thOpiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
finance.yahoo.com - November 1 at 8:17 AM
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of DirectorsOpiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
finance.yahoo.com - October 29 at 8:28 AM
Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry DayOpiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
finance.yahoo.com - October 22 at 8:26 AM
Opiant Pharmaceuticals OPNT005 receives grant for development of a heroin vaccineOpiant Pharmaceuticals' OPNT005 receives grant for development of a heroin vaccine
seekingalpha.com - October 18 at 5:01 PM
Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin VaccineOpiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine
finance.yahoo.com - October 18 at 8:36 AM
OPNT: Contract with BARDA to Support Develop of OPNT003…OPNT: Contract with BARDA to Support Develop of OPNT003…
finance.yahoo.com - October 4 at 4:49 PM
Opiant nets $12.7M in equity offeringOpiant nets $12.7M in equity offering
seekingalpha.com - September 28 at 4:55 PM
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesOpiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - September 28 at 4:55 PM
Opiant Pharmaceuticals to Present at the Cantor Global Healthcare ConferenceOpiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
finance.yahoo.com - September 26 at 8:36 AM
Opiant prices stock offering at $17; shares down 19% premarketOpiant prices stock offering at $17; shares down 19% premarket
seekingalpha.com - September 25 at 4:55 PM
Opiant Pharmaceuticals Announces Pricing of Public Offering of Common StockOpiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 25 at 4:55 PM
Opiant Pharmaceuticals Announces Proposed Public Offering of Common StockOpiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 24 at 4:54 PM
Opiant nabs BARDA funding up to $4.6M for opioid overdose med; shares up 7% after hoursOpiant nabs BARDA funding up to $4.6M for opioid overdose med; shares up 7% after hours
seekingalpha.com - September 21 at 8:30 AM
Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - September 20 at 4:51 PM
How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?
finance.yahoo.com - September 14 at 4:55 PM
Opnet Technologies, Inc. (OPNT) Reports Manufacturing Pact with Consort Medical Plc for OPNT003Opnet Technologies, Inc. (OPNT) Reports Manufacturing Pact with Consort Medical Plc for OPNT003
www.streetinsider.com - September 12 at 8:26 AM
Opiant Pharmaceuticals signs manufacturing agreement with Consort Medical for OPNT003 for treatment of opioid overdoseOpiant Pharmaceuticals signs manufacturing agreement with Consort Medical for OPNT003 for treatment of opioid overdose
seekingalpha.com - September 10 at 4:52 PM
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - September 10 at 8:30 AM
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia NervosaOpiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
globenewswire.com - September 5 at 8:32 AM
UPDATE: Opiant Pharmaceuticals, Inc. (OPNT) Reports Final Patient Enrolled in Phase 2 Clinical Trial Evaluating ...UPDATE: Opiant Pharmaceuticals, Inc. (OPNT) Reports Final Patient Enrolled in Phase 2 Clinical Trial Evaluating ...
www.streetinsider.com - September 4 at 5:02 PM
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia ...Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia ...
www.nasdaq.com - September 4 at 8:34 AM
Opiant Pharma up 73% premarket on EBS takeout of Adapt PharmaOpiant Pharma up 73% premarket on EBS takeout of Adapt Pharma
seekingalpha.com - August 29 at 4:54 PM
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel